July 2026 in “Frontiers in Oncology” This mini review reports on papulopustular eruptions linked to classical EGFR inhibitors, MEK inhibitors, and amivantamab, highlighting distinct dermatologic toxicities in each treatment context and exploring underlying mechanisms and management strategies.
August 2024 in “Postgraduate Medical Journal” A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.
9 citations
,
October 2015 in “Journal of Cutaneous Pathology” This study found that histopathologic features of erythematous papulopustular eruption due to EGFR inhibitors vary with eruption severity and differ between cetuximab and erlotinib treatments.
29 citations
,
January 2012 in “Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy” This review discusses the various skin, mucosa, and adnexa side effects associated with different chemotherapeutic agents and provides insights into their clinical presentation and management; it reports no new results.
November 2023 in “Journal of Investigative Dermatology” EGFR-targeted cancer therapy can cause skin issues starting at hair follicles, leading to inflammation.